Bliss GVS Pharma's Q2 FY25 financials show mixed performance, MarketsMOJO advises 'Hold' on stock
Bliss GVS Pharma, a smallcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.
According to the financials, Bliss GVS Pharma has seen a negative performance in the quarter, with a score of -15 compared to 14 in the previous three months. However, there are some positive aspects to the company’s financials. The operating cash flow for the past three years has been the highest at Rs 152.45 crore, indicating a strong generation of cash from business operations. Additionally, the net sales for the quarter were the highest in the last five quarters at Rs 217.68 crore, showing a positive trend in sales.
On the other hand, there are some areas of concern for Bliss GVS Pharma. The profit before tax (PBT) less other income for the quarter has fallen by -34.09% year on year, indicating a negative trend in the near term. Similarly, the profit after tax (PAT) for the quarter has also fallen by -42.7% year on year, showing a negative trend in the near term. The interest cost for the quarter has also increased by 150.33% quarter on quarter, which could be a result of increased borrowings. This is further reflected in the company’s lowest operating profit to interest ratio in the last five quarters.
Overall, the financial results for the quarter ending September 2024 show a mixed performance for Bliss GVS Pharma. While there are some positive aspects, there are also areas of concern that the company needs to address in order to improve its financial performance. Investors are advised to hold their position in the stock for now, as recommended by MarketsMOJO.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
